Key result
Intravenous zatebradine prolonged sinus cycle length by 16 and 17% and altered atrioventricular node conduction compared to placebo.
Why the study?
Does intravenous zatebradine alter electrophysiologic properties in patients without structural heart disease?
RCT (n=35)
Double-blind
randomized
Does intravenous zatebradine alter electrophysiologic properties in patients without structural heart disease?
Zatebradine, a sinus node inhibitor, significantly alters both sinus node and atrioventricular node conduction and refractory properties in humans.
Answers are grounded in this paper and cite their sources.
Informs rate-control drug selection in patients without heart disease; extends animal sinus node data to human electrophysiology.
The purpose of this study was to evaluate the electrophysiologic effects of zatebradine, a sinus node inhibitor, in human subjects. Patients without structural heart disease were randomized to receive intravenous zatebradine (23 patients) or placebo (12 patients). Electrophysiologic measures were obtained at baseline and repeated at 40 and 70 min after drug administration. In the placebo group, there were no significant changes in any parameter over time. After zatebradine, sinus node function changed significantly at 40 min, with no further change at 70 min; sinus cycle length was prolonged by 16 and 17% (p < 0.001), and corrected sinus node recovery time was prolonged by 30 and 22% (p = 0.008). Similarly, atrioventricular node function changed significantly at 40 min, with no further change at 70 min; atrio-His interval was prolonged by 15 and 15% (p = 0.02), atrioventricular node effective refractory period was prolonged by 12 and 11% (p = 0.01), and Wenckebach cycle length was prolonged by 15 and 11% (p = 0.002). Atrial refractoriness, His-Purkinje conduction, ventricular refractoriness, and action-potential duration were not affected by zatebradine. Zatebradine, a sinus node inhibitor, alters the conduction and refractory properties of the human atrioventricular node, in addition to the expected effect on sinus node function.
No takes yet. Share an insight, caveat, or question.
Chiamvimonvat et al. (1998) conducted an RCT in Without structural heart disease (n=35). Zatebradine vs. Placebo was evaluated on Sinus cycle length (16 and 17% prolongation, p=<0.001). Intravenous zatebradine prolonged sinus cycle length by 16 and 17% and altered atrioventricular node conduction compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: